Mortality and healthcare costs in Medicare beneficiaries with AL amyloidosis. J Comp Eff Res 2018 Nov;7(11):1053-1062
Date
10/26/2018Pubmed ID
30354284DOI
10.2217/cer-2018-0062Scopus ID
2-s2.0-85056393482 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
AIMS: Examine mortality and healthcare costs in Medicare beneficiaries with newly diagnosed immunoglobulin light chain (AL) amyloidosis.
PATIENTS & METHODS: Cases were identified in 2012-2015 Medicare 5% data with ≥1 inpatient/≥2 outpatient claims consistent with AL amyloidosis and ≥1 AL-specific treatment. Cases were matched 3:1 with disease-free controls. Descriptive statistics were reported.
RESULTS: A total of 249 (33.3%) cases were matched to 747 (66.7%) controls. A total of 19.7% of cases died within 1 year of follow-up versus 5.5% of controls; 30.6 versus 11.8% died within 2 years (p < 0.001). Mean (SD) costs in 1-year of follow-up were significantly higher among cases versus controls ($71,040 [65,766] vs $13,722 [27,493]; p < 0.001).
CONCLUSION: Mortality was nearly four-times higher, and costs nearly five-times higher in beneficiaries with AL amyloidosis versus controls.
Author List
Quock TP, Chang E, Munday JS, D'Souza A, Gokhale S, Yan TAuthor
Anita D'Souza MD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AgedAged, 80 and over
Case-Control Studies
Female
Health Care Costs
Humans
Immunoglobulin Light-chain Amyloidosis
Inpatients
Male
Medicare
Retrospective Studies
United States